“…Furthermore, it is important to take away misconceptions that smokers have about the value of these therapies. This is important for the ultimate aim of increasing the likelihood to use these therapies during a quit attempt and increase the chance to successfully stop smoking (Fucito & Juliano, 2007;Vogt, Ashworth, Hall, Sniehotta, & Marteau, 2010;Willemsen, Wiebing, Emst, & Zeeman, 2006). We therefore conducted a qualitative study to explore knowledge and expectations about nicotine vaccination in a group of smokers who applied for participation in a phase II-b, randomized trial on the efficacy of the nicotine vaccine "NicVAX," co-administered with the partial nicotine acetylcholine agonist varenicline and intensive counseling .…”